The relationship between antitumor effects and relative dose intensity of S-1 plus cisplatin treatment for metastatic gastric cancer.
The relationship between antitumor effects and relative dose intensity of S-1 plus cisplatin treatment for metastatic gastric cancer.
复制标题
S-1联合顺铂治疗转移性胃癌的抗肿瘤作用与相对剂量强度的关系。
作者：
M. Kitagawa;T. Shimura;Tomonori Yamada;M. Ebi;Yoshikazu Hirata;T. Mizoshita;S. Tanida;H. Kataoka;T. Kamiya;T. Joh
背景/目的
S-1加顺铂是日本转移性胃癌（MGC）的标准一线化疗，但剂量强度与抗肿瘤作用之间的关系尚不清楚。
患者和方法
我们回顾性研究了2006年1月至2010年12月在两家日本医院接受S-1联合顺铂治疗MGC的64例患者。
结果
S-1+顺铂的中位相对剂量强度（RDI）为87%（范围：59.5%-100%）。通过肿瘤缓解的受试者操作特征分析，确定S-1+顺铂的RDI临界值为80%。在RDI<80%（n=19）和RDI≥80%（n=45）组中，缓解率分别为20.0%和37.5%（p=0.182），中位生存时间分别为394和376天（p=0.915），中位无进展生存期（PFS）分别为188和170天（p=0.851）。
结论
在姑息治疗环境中，允许MGC患者适当降低RDI。
BACKGROUND/AIM
S-1 plus cisplatin is the standard first-line chemotherapy for metastatic gastric cancer (MGC) in Japan, but the relationship between dose intensity and antitumor effects remains unclear.
PATIENTS AND METHODS
We retrospectively studied 64 patients who received S-1 plus cisplatin for MGC from January 2006 to December 2010 in two Japanese hospitals.
RESULTS
The median relative dose intensity (RDI) of S-1 plus cisplatin was 87% (range, 59.5%-100%). The cut-off value of RDI of S-1 plus cisplatin was identified to be 80% by a receiver operating characteristic analysis of the tumor response. In the RDI<80% (n=19) and the RDI≥80% (n=45) groups, the response rates were 20.0% and 37.5% (p=0.182), the median survival times were 394 and 376 days (p=0.915), and the median progression-free survival (PFS) was 188 and 170 days (p=0.851), respectively.
CONCLUSION
An appropriate RDI reduction may be permitted for patients with MGC in palliative settings.